Humanwell Puracap announced today that the FDA approved its ANDA221049, paving the way for the launch of a generic alternative as the market moves into 2026. This regulatory approval is expected to significantly impact the segment by enabling the company to compete directly with existing branded products in a market projected to expand in the coming years.